Lu Can C - OmicsDI

Show results for

Unknown (6256)
Transcriptomics (172)
Proteomics (146)
Metabolomics (44)
Genomics (33)
Models (4)
Other (1)

Organisms

Homo sapiens (173)
Mus musculus (74)
Rattus norvegicus (8)
Arabidopsis thaliana (8)
Gallus gallus (6)
Saccharomyces cerevisiae (6)
Escherichia coli (6)
Oryza sativa (5)
Sus scrofa (3)
Drosophila melanogaster (3)
Severe acute respiratory syndrome coronavirus 2 (3)
Oryza sativa Japonica Group (2)
Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 (2)
Macaca mulatta (2)
Cronobacter sakazakii ATCC BAA-894 (2)
Escherichia coli K-12 (1)
Flaveria cronquistii (1)
activated sludge metagenome (1)
Amphimedon queenslandica (1)
Actinobacillus pleuropneumoniae serovar 1 str. 4074 (1)
human gut metagenome (1)
Schistosoma japonicum (1)
Coregonus clupeaformis (1)
Salmonella enterica (1)
Brassica oleracea var. alboglabra (1)
Malus domestica (1)
Zea mays (1)
Populus trichocarpa (1)
Caenorhabditis elegans (1)
Danio rerio (1)

Organisms

Homo sapiens (3)

Repository

biostudies-arrayexpress (193)
pride (82)
MetaboLights (43)
iProX (41)
MassIVE (17)
EGA (8)
PanoramaPublic (6)
ENA (4)
BioModels (3)
geo (2)
Cell Collective (1)
GNPS (1)

Tissue

Cell culture (23)
Epithelial cell (6)
B cell (3)
Blood serum (3)
Liver (3)
Lung (3)
Malignant cell (3)
Blood cell (2)
Brain (2)
Breast (2)
Embryonic stem cell (2)
Keratinocyte (2)
Lymph (2)
Skin (2)
Blood (1)
Blood cancer cell (1)
Blood plasma (1)
Cell suspension culture (1)
Early embryonic cell (1)
Epithelial cell of cervix (1)
Esophageal squamous cell carcinoma cell line (1)
Excretion (1)
Gut (1)
HEK-293T cell (1)
HeLa cell (1)
Heart (1)
Heart development (1)
Ileum (1)
Kidney (1)
Leaf (1)

Disease

Breast cancer (3)
Acute leukemia (2)
Disease free (2)
Inflammatory bowel disease (2)
Neuroblastoma (2)
Avian influenza (1)
Brain cancer (1)
Cardiomyopathy (1)
Cervix carcinoma (1)
Esophageal carcinoma (1)
Fragile X syndrome (1)
Inflammatory bowel disease 1 (1)
Long COVID (1)
Lymphoma (1)
Malignant neoplasm of ovary (1)
Ovarian cancer (1)
Scabies (1)
Type 2 diabetes mellitus (1)

Technology Type

Mass Spectrometry (82)
Shotgun proteomics (42)
Mass spectrometry (39)
Bottom-up proteomics (12)
Data-dependent acquisition (11)
Data-independent acquisition (8)
NMR spectroscopy (4)
Chemical cross-linking coupled with mass spectrometry proteomics (4)
Gel-based experiment (3)
SWATH MS (3)
Top-down proteomics (3)
Affinity purification coupled with mass spectrometry proteomics (2)
Affymetrix/Illumina (1)
Illumina HiSeq 2000 (1)
Mass spectrometry assay (1)
Glycoproteomics (1)
Immunopeptidomics (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse phase (17)
Liquid Chromatography MS - negative - reverse phase (16)
Orbitrap Fusion Lumos (7)
Illumina HiSeq 2000 (5)
NextSeq 500 (4)
Illumina NovaSeq 6000 (3)
Q Exactive Plus (3)
Illumina HiSeq 4000 (2)
LTQ (2)
LTQ XL (2)
Q Exactive (2)
5975C Series GC/MSD (Agilent) (2)
Bruker (2)
Gas Chromatography MS - Positive (GC-MS (Positive)) (2)
Gas Chromatography MS - positive (2)
Liquid Chromatography MS - (2)
Liquid Chromatography MS - alternating - hilic (2)
Nuclear Magnetic Resonance (NMR) - (2)
Illumina Genome Analyzer IIx (1)
DNBSEQ-T7 (1)
Illumina MiSeq (1)
Illumina HiSeq 2500 (1)
Orbitrap Exploris 480 (1)
LTQ Orbitrap Elite (1)
Orbitrap Fusion (1)
Orbitrap Fusion ETD (1)
SolariX (1)
6460 Triple Quadrupole LC/MS (Agilent) (1)
API 4000 QTRAP (AB Sciex) (1)
Agilent 5975E GC/MSD (Agilent) (1)

Publication Date

2015 (36)
2024 (35)
2025 (30)
2022 (30)
2012 (29)
2023 (28)
2021 (28)
2014 (23)
2013 (20)
2016 (17)
2026 (17)
2010 (16)
2008 (15)
2011 (13)
2009 (11)
2017 (10)
2019 (9)
2020 (6)
2018 (4)
2007 (2)
2006 (2)
2005 (1)
2002 (1)

UNIPROT ID/AC

P00573 (1)
P07659 (1)
P42212 (1)

CHEBI ID

CHEBI:30769 (15)
CHEBI:15428 (14)
CHEBI:16704 (13)
CHEBI:17295 (13)
CHEBI:18012 (13)
CHEBI:16335 (12)
CHEBI:16919 (12)
CHEBI:17895 (12)
CHEBI:27897 (12)
CHEBI:15756 (11)
CHEBI:15971 (11)
CHEBI:17509 (11)
CHEBI:18019 (11)
CHEBI:20067 (11)
CHEBI:28300 (11)
CHEBI:15729 (10)
CHEBI:15741 (10)
CHEBI:16015 (10)
CHEBI:16393 (10)
CHEBI:16566 (10)
CHEBI:16750 (10)
CHEBI:17351 (10)
CHEBI:17596 (10)
CHEBI:17992 (10)
CHEBI:26271 (10)
CHEBI:26986 (10)
CHEBI:30915 (10)
CHEBI:17535 (1)
CHEBI:33697 (1)
CHEBI:33699 (1)

Metabolite Name

Creatine (8)
Pyruvic acid (8)
Arachidonic acid (7)
Cholic acid (7)
Guanosine (7)
L-Histidine (7)
Linoleic acid (7)
Taurine (7)
Adenosine (6)
Citric acid (6)
Citrulline (6)
Glycerophosphocholine (6)
Glycine (6)
L-Asparagine (6)
Uric acid (6)
3-Hydroxybutyric acid (5)
Adenine (5)
Adipic acid (5)
Ascorbic acid (5)
Azelaic acid (5)
Benzoic acid (5)
Choline (5)
Citraconic acid (5)
Citramalic acid (5)
Glutamine (5)
Glutaric acid (5)
Hypoxanthine (5)
Inosine (5)
L-Arginine (5)
L-Lysine (5)

IsPrivate

False (3)

First Public Date

2026 (1)
2024 (1)
2022 (1)
2015 (1)

Modelling Approach

Ordinary differential equation model (3)

Study type

Transcription profiling by array (102)
RNA-seq of coding RNA (38)
ChIP-seq (11)
Methylation profiling by high throughput sequencing (10)
Comparative genomic hybridization by array (9)
RNA-seq of non coding RNA (6)
Unknown experiment type (5)
ATAC-seq (3)
Methylation profiling by array (2)
RNA-seq of total RNA (2)
Whole chromosome random sequencing (1)
Spatial transcriptomics by high-throughput sequencing (1)
Other (1)
RNA-seq of coding RNA from single cells (1)

Release Date

2022 (892)
2023 (866)
2024 (768)
2025 (709)
2021 (668)
2020 (466)
2019 (347)
2018 (292)
2017 (242)
2016 (242)
2015 (224)
2014 (174)
2013 (115)
2012 (111)
2026 (98)
2011 (64)
2010 (55)
2008 (40)
2009 (29)
2007 (16)
2006 (9)
2005 (6)
2002 (5)
2004 (4)
2003 (2)
2001 (2)
2000 (2)
1998 (1)

Lab affiliation

BGI Research (2)
Fudan University (2)
School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China (2)
2Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, Madison, WI 53705, USA (1)
Beijing Key Laboratory of Antimicrobial Agents, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College (1)
Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China. (1)
Cambridge Institute for Medical Research, Department of Clinical Neurosciences, Clinical School, University of Cambridge, Cambridge, CB2 0XY, UK (1)
Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver V5Z 1L3, Canada. (1)
Cancer Institute, Fudan University Shanghai Cancer Center (1)
Center for Innovative Engineering Technology in Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine, Shenyang, China (1)
Children's Hospital of Philadelphia (1)
Chongqing Medical University (1)
College of Biomedical Engineering & Instrument Science,Zhejiang University (1)
College of life sciences and technology,Guangxi University (1)
Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, United States (1)
Department of Archaeology, Max Planck Institute for the Science of Human History, Jena, Germany. (1)
Department of Biochemistry and Molecular Biophysics, Columbia University Irving Medical Center, New York, NY, United States (1)
Department of Biology, Massachusetts Institute of Technology, Building 68, 31 Ames St., Cambridge, MA 02139 Howard Hughes Medical Institute, Chevy Chase, MD (1)
Department of Cancer Research and Molecular Medicine Faculty of Medicine Laboratory Centre, 5th floor. Erling Skjalgssons gt. 1 Norwegian University of Science and Technology NTNU 7006 Trondheim, Norway Tel: +47 72573076; Fax: +47 72576400 Cell. phone: +47 91825455 (1)
Department of Integrated Immunobiology Duke School of Medicine Durham, NC, USA (1)
Department of Life Science, National Taiwan University, Taiwan (1)
Department of Medical Genetics, University of British Columbia, Vancouver, Canada (1)
Department of Medical Protein Research, VIB & Department of Biochemistry, UGent, Ghent, Belgium (1)
Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, Hu Bei Province, 430060, China (1)
Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China (1)
Department of Proteomics and Signal Transduction, Max-Planck Institute of Biochemistry, Am Klopferspitz 18, Martinsried, Germany (1)
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, 10065, USA (1)
Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA (1)
Department of Toxicology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China tel:17534997727 (1)
Department of pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China (1)

Tags

xref:PubMed:36450980 (1)
xref:PubMed:38228145 (1)

Previous page
1 / 666
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 666
Next page

Sort by:

Relevance

Page size

Glycophorin-C sialylation regulates Lu/BCAM adhesive capacity during erythrocyte aging.

Not available

S-EPMC5761629 | biostudies-literature

Encapsulation of a radiolabeled cluster inside a fullerene cage, (177)Lu(x)Lu((3-x))N@C(80): an interleukin-13-conjugated radiolabeled metallofullerene platform.

Not available

S-EPMC2875150 | biostudies-literature

Optimization of the radiosynthesis of the PSMA-targeting drugs [177Lu]Lu-P17-087 and [177Lu]Lu-P17-088 on the MiniLu™ automated module.

Not available

S-EPMC12623512 | biostudies-literature

Stable Unpaired Electron States in the Lu-Lu Bond Leading to the Absence of Odd-Even Parity in the Kondo Effect of Lu2@C82 Transistors.

Not available

S-EPMC12005644 | biostudies-literature

Characterization of [¹¹C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain.

Not available

S-EPMC5215309 | biostudies-literature

RNA-Seq analysis of subcutaneous patient-derived neuroblastoma xenografts (LU-NB-3R): Comparison of BAY390, A967079, and vehicle controls

Neuroblastoma (NB) is a pediatric cancer characterized by significant heterogeneity and poor prognosis, particularly in high-risk cases with MYCN amplification. Understanding the molecular response of neuroblastoma to different treatments can provide valuable insights into potential therapeutic stra...

ORGANISM(S): Homo sapiens

2026-04-01 | E-MTAB-15002 | biostudies-arrayexpress

Promising potential of [¹⁷⁷Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy-a preclinical study using a syngeneic breast cancer model.

Not available

S-EPMC8041666 | biostudies-literature

Integrated microbiome-metabolome-genome axis data of Laiwu and Lulai pigs

Excessive fat deposition can trigger metabolic diseases, and it is crucial to identify factors that can break the link between fat deposition and metabolic diseases. Healthy obese Laiwu pigs (LW) are high in fat content but resistant to metabolic diseases. In this study, we compared the fecal microb...

2023-04-20 | MTBLS3977 | MetaboLights

Radionuclide Therapy of HER2-Expressing Xenografts Using [¹⁷⁷Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab.

Not available

S-EPMC10177614 | biostudies-literature

RNA-seq of tumor organoids from patient-derived xenograft (PDX, LU-NB-2) of high-risk, MYCN-amplified neuroblastoma treated with prochlorperazine (PCZ), pitavastatin (PIT), the combination of both drugs, and untreated controls.

Neuroblastoma (NB) is a pediatric cancer characterized by significant heterogeneity and poor prognosis, especially in high-risk cases with MYCN amplification. Understanding the molecular response of neuroblastoma to different treatments can provide insights into potential therapeutic strategies. The...

2025-05-25 | E-MTAB-14846 | biostudies-arrayexpress

Previous page
1 / 666
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 666
Next page

Sort by:

Relevance

Page size

6657 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

CHEBI ID

Metabolite Name

IsPrivate

First Public Date

Modelling Approach

Study type

Release Date

Lab affiliation

Tags

OmicsDI is part of the ELIXIR infrastructure

Tweets